Subscribe
bee32
bee32 / iStockphoto.com
31 October 2017Americas

PTAB grants rehearing of Genentech patent IPR

The Patent Trial and Appeal Board (PTAB) has agreed to rehear an inter partes review (IPR) filed by Hospira, a company now owned by Pfizer.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
PTAB denies Celltrion’s patent challenge against Genentech
7 March 2017   The Patent Trial and Appeal Board has rejected Celltrion’s challenge against a Genentech patent centring on a method of treating rheumatoid arthritis, stating that the challenged patent did not show any reasonable likelihood of being invalid.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Americas
PTAB denies Celltrion’s patent challenge against Genentech
7 March 2017   The Patent Trial and Appeal Board has rejected Celltrion’s challenge against a Genentech patent centring on a method of treating rheumatoid arthritis, stating that the challenged patent did not show any reasonable likelihood of being invalid.

More on this story

Americas
PTAB denies Celltrion’s patent challenge against Genentech
7 March 2017   The Patent Trial and Appeal Board has rejected Celltrion’s challenge against a Genentech patent centring on a method of treating rheumatoid arthritis, stating that the challenged patent did not show any reasonable likelihood of being invalid.

More features

Gilead awarded $30m over counterfeit HIV drug scheme
EPO invalidates human milk patent after Nestle opposition
Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic